All peptides, including fluorescein isothiocyanate (FITC)-labeled p53 TAD (42-57), were manufactured by Dandicure (Ochang, Korea) at a purity of 95%
However, recent evidence also reveals TDP-43 accumulations in the nucleus, not only in the cytoplasm 11,12
Our findings, which utilize a novel CSMN reporter line with TDP-43 pathology, not only reveal the presence of metabolomic defects at an early stage of the disease, but also suggest that proper modulation of metabolomic imbalance could offer therapeutic strategies to improve the integrity of mitochondria, and thus the health of diseased UMNs
Pharmacies that compounded these peptides operated under legal uncertainty
Provide Evidence-Based Guidance: Discuss the current scientific understanding of BPC-157, weighing its potential benefits against the current limitations